Hyderabad News Desk

Atopic Dermatitis Pipeline, Clinical Trials Studies, Emerging Drugs, Mergers and Acquisition, Licensing, Agreements & Collaborations, and Latest News 2023 (Updated)

 Breaking News
  • No posts were found

Atopic Dermatitis Pipeline, Clinical Trials Studies, Emerging Drugs, Mergers and Acquisition, Licensing, Agreements & Collaborations, and Latest News 2023 (Updated)

November 10
20:31 2023
Atopic Dermatitis Pipeline, Clinical Trials Studies, Emerging Drugs, Mergers and Acquisition, Licensing, Agreements & Collaborations, and Latest News 2023 (Updated)

DelveInsight’s, “Atopic Dermatitis Pipeline Insight 2023” report provides comprehensive insights about 100+ companies and 110+ pipeline drugs in the Atopic Dermatitis pipeline landscape. It covers the Atopic Dermatitis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Atopic Dermatitis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Atopic Dermatitis Pipeline Report

  • DelveInsight’s Atopic Dermatitis pipeline report depicts a robust space with 100+ active players working to develop 110+ pipeline therapies for Atopic Dermatitis treatment.
  • The leading companies working in the Atopic Dermatitis Market include Dermavant Sciences, Pfizer, AOBiome, Allakos Inc., E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd., Eli Lilly and Company, Vanda Pharmaceuticals, Suzhou Connect Biopharmaceuticals, Arcutis Biotherapeutics, Reistone Biopharma, Alphyn Biologics, Argenx, Shulov Innovate for Science, Teres Bio, Qurient Co, Sun Pharmaceutical, Merck Sharp & Dohme LLC, Hangzhou Yirui Pharmaceutical Technology Co., Ltd, GI Innovation, AnaptysBio, MC2 therapeutics, Akaal Pharma, Kiniksa Pharmaceuticals, Selection, Intrinsic Medicine, Genome & Company, TWi Biotechnology, and others.
  • Promising Atopic Dermatitis Pipeline Therapies in the various stages of development include Baricitinib, Topical corticosteroid, si-544, Lebrikizumab, MEDI9929, and others.
  • November 2023: AbbVie announced a study of Phase 4 clinical trials for vUpadacitinib. The study is comprised of a 12-week double-blind period, followed by a 12-week single-blind period. Participants will receive upadacitinib oral tablets once daily for up to 24 weeks. A Phase 3b/4 Randomized, Blinded, Treat-to-Target and Dose-Flexibility Study of Upadacitinib in Adult Subjects With Moderate to Severe Atopic Dermatitis.
  • November 2023: Opsidio LLC announced a study of Phase 2 clinical trials for OpSCF. The purpose of this study is to determine the efficacy and safety of a monoclonal antibody, OpSCF, in the treatment of adults with moderate to severe Atopic Dermatitis (Eczema). OpSCF will be compared to a placebo.
  • November 2023: Pfizer announced a study of Phase 2 clinical trials for PF-07275315 and PF-07264660. The purpose of this study is to learn about the safety and effects of 2 study medicines (PF-07275315 and PF-07264660) for the treatment of atopic dermatitis (AD). AD is a long- lasting itchy red rash, caused by a skin reaction.
  • November 2023: Q32 Bio Inc. announced a study of Phase 2 clinical trials for ADX-914. This is a phase IIa, randomized, double-blind, placebo-controlled, multi-center proof-of-concept (POC) study in subjects with moderate to severe Atopic Dermatitis. This is a two-part phase IIa, randomized, double-blind, placebo-controlled, multi-center proof-of-concept (POC) study in adult subjects with persistent moderate to severe Atopic Dermatitis (AD). ADX-914 or matching placebo for administered subcutaneously in the clinic setting every 2 weeks for 12 weeks, and follow-up for 12 weeks. ADX-914 or matching placebo will be in the clinic setting post-randomization. In Part A, up to 3 cohorts of subjects will be randomized 2:1 drug vs placebo. In Part B subjects will be randomized 1:1 to drug vs placebo at a doses selected in Part A.

 

Request a sample and discover the recent advances in Atopic Dermatitis Treatment Drugs @ Atopic Dermatitis Pipeline Report

 

In the Atopic Dermatitis pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Atopic Dermatitis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Atopic Dermatitis Overview

Atopic dermatitis (AD) also called eczema, is a chronic condition and the most common type of skin inflammation that usually starts in early childhood, but can occur at any age and can be recurrent or persistent throughout life. In the word ‘dermatitis,’ ‘derm’ means ‘skin’ and ‘itis’ means ‘inflammation.’ Thus, dermatitis is a skin inflammation characterized by itchiness, redness and a rash caused by genetics, an overactive immune system, infections, allergies, and irritating substances.

 

Find out more about Atopic Dermatitis Therapeutics Assessment @ Atopic Dermatitis Preclinical and Discovery Stage Products

 

Atopic Dermatitis Emerging Drugs Profile

  • Tapinarof: Dermavant Sciences
  • Etrasimod: Pfizer
  • B244: AOBiome
  • Lirentelimab: Allakos Inc.
  • QY201: E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.

 

Atopic Dermatitis Pipeline Therapeutics Assessment

There are approx. 100+ key companies which are developing the Atopic Dermatitis therapies. The Atopic Dermatitis companies which have their Atopic Dermatitis drug candidates in the most advanced stage, i.e. phase III include, Dermavant Sciences.

 

DelveInsight’s Atopic Dermatitis pipeline report covers around 110+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates

 

Atopic Dermatitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Intravenous
  • Subcutaneous
  • Parenteral
  • Topical

 

Atopic Dermatitis Pipeline Products have been categorized under various Molecule types such as

  • Recombinant fusion proteins
  • Small molecule
  • Monoclonal antibody
  • Peptide
  • Polymer
  • Gene therapy

 

Learn more about the emerging Atopic Dermatitis Pipeline Therapies @ Atopic Dermatitis Clinical Trials Assessment

 

Scope of the Atopic Dermatitis Pipeline Report

  • Coverage- Global
  • Atopic Dermatitis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Atopic Dermatitis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
  • Atopic Dermatitis Companies- Dermavant Sciences, Pfizer, AOBiome, Allakos Inc., E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd., Eli Lilly and Company, Vanda Pharmaceuticals, Suzhou Connect Biopharmaceuticals, Arcutis Biotherapeutics, Reistone Biopharma, Alphyn Biologics, Argenx, Shulov Innovate for Science, Teres Bio, Qurient Co, Sun Pharmaceutical, Merck Sharp & Dohme LLC, Hangzhou Yirui Pharmaceutical Technology Co., Ltd, GI Innovation, AnaptysBio, MC2 therapeutics, Akaal Pharma, Kiniksa Pharmaceuticals, Selection, Intrinsic Medicine, Genome & Company, TWi Biotechnology, and others.
  • Atopic Dermatitis Pipeline Therapies- Baricitinib, Topical corticosteroid, si-544, Lebrikizumab, MEDI9929, and others.

 

Dive deep into rich insights for new drugs for Atopic Dermatitis Treatment, Visit @ Atopic Dermatitis Market Drivers and Barriers, and Future Perspective

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Atopic Dermatitis: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Atopic Dermatitis– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Tapinarof: Dermavant Sciences
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. B244: AOBiome
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I/II)
  14. QY201: E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. EP262: Escient Pharmaceuticals
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Atopic Dermatitis Key Companies
  21. Atopic Dermatitis Key Products
  22. Atopic Dermatitis- Unmet Needs
  23. Atopic Dermatitis- Market Drivers and Barriers
  24. Atopic Dermatitis- Future Perspectives and Conclusion
  25. Atopic Dermatitis Analyst Views
  26. Atopic Dermatitis Key Companies
  27. Appendix

 

For further information on the Atopic Dermatitis Pipeline therapeutics, reach out to Atopic Dermatitis Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services

Categories